JOHNSON & JOHNSON JNJ

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company's primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.

The Chief Operating Decision Maker (CODM) is the Company's Chief Executive Officer (Principal Executive Officer). The Executive Committee is Johnson & Johnson's senior leadership team responsible for setting the strategy and priorities of the Company and driving accountability at all levels. Within the strategic parameters provided by the Executive Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.

Last close 263.81 2026-10-23
Market cap $635.76B 2026-06-28 share count
52-week range 184.66 - 281.07

Valuation FY2025 figures against the last close

P/S6.7x
P/E23.9x
P/FCF32.3x
EV/EBITDA—
Dividend yield—
Diluted EPS11.03

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $94.19B$88.82B$85.16B$79.99B$78.74B$82.58B$82.06B$81.58B$76.45B$71.89B
Cost of revenue $30.26B$27.47B$26.55B$24.60B$23.40B$28.43B$27.56B$27.09B$25.44B$21.79B
Gross profit $63.94B$61.35B$58.61B$55.39B$55.34B$54.16B$54.50B$54.49B$51.01B$50.10B
R&D $109.0M$1.84B$483.0M$0$0—————
SG&A $23.68B$22.87B$21.51B$20.25B$20.12B$22.08B$22.18B$22.54B$21.52B$20.07B
Interest expense $971.0M$755.0M$772.0M$276.0M$183.0M$201.0M$318.0M$1.00B$934.0M$726.0M
Pre-tax income $32.58B$16.69B$15.06B$19.36B$19.18B$16.50B$17.33B$18.00B$17.67B$19.80B
Income tax $5.78B$2.62B$1.74B$2.99B$1.38B$1.78B$2.21B$2.70B$16.37B$3.26B
Net income $26.80B$14.07B$35.15B$17.94B$20.88B$14.71B$15.12B$15.30B$1.30B$16.54B
EPS, basic 11.135.8413.886.837.935.595.725.700.486.04
EPS, diluted 11.035.7913.726.737.815.515.635.610.475.93
Shares, diluted (wtd. avg.) 2.43B2.43B2.56B2.66B2.67B2.67B2.68B2.73B2.75B2.79B

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $19.71B$24.11B$21.86B$14.13B$14.49B$13.98B$17.30B$18.11B$17.82B$18.97B
Short-term investments $393.0M$417.0M$1.07B$9.39B$17.12B$11.20B$1.98B$1.58B$472.0M$22.93B
Receivables $17.18B$14.84B$14.87B$14.04B$15.28B$13.58B$14.48B$14.10B$13.49B$11.70B
Inventory $14.19B$12.44B$11.18B$10.27B$10.39B$9.34B$9.02B$8.60B$8.77B$8.14B
Total current assets $55.62B$55.89B$53.49B$55.29B$60.98B$51.24B$45.27B$46.03B$43.09B$65.03B
Property, plant and equipment $23.17B$20.52B$19.90B$17.98B$18.96B$18.77B$17.66B$17.04B$17.00B$15.91B
Goodwill $48.77B$44.20B$36.56B$36.05B$25.44B$36.39B$33.64B$30.45B$31.91B$22.80B
Other intangibles $50.40B$37.62B$34.17B$38.49B$46.39B$53.40B$47.64B$47.61B$53.23B$26.88B
Total assets $199.21B$180.10B$167.56B$187.38B$182.02B$174.89B$157.73B$152.95B$157.30B$141.21B
Accounts payable $11.99B$10.31B$9.63B$9.89B$11.05B$9.51B$8.54B$7.54B$7.31B$6.92B
Short-term debt $2.00B$1.75B$1.47B$1.55B$2.13B$1.80B$1.20B$2.80B$1.50B$1.70B
Total current liabilities $54.13B$50.32B$46.28B$55.80B$45.23B$42.49B$35.96B$31.23B$30.54B$26.29B
Long-term debt $39.44B$30.65B$25.88B$26.89B$29.98B$32.63B$26.49B$27.68B$30.68B$22.44B
Total liabilities $117.67B$108.61B$98.78B$110.57B$108.00B$111.62B$98.26B$93.20B$97.14B$70.79B
Retained earnings $168.98B$155.79B$153.84B$128.34B$123.06B$113.89B$110.66B$106.22B$101.79B$110.55B
Total equity $81.54B$71.49B$68.77B$76.80B$74.02B$63.28B$59.47B$59.75B$60.16B$70.42B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $24.53B$24.27B$22.79B$21.19B$23.41B$23.54B$23.42B$22.20B$21.06B$18.77B
Depreciation and amortisation $7.50B$7.34B$7.49B$6.97B$7.39B$7.23B$7.01B$6.93B$5.64B$3.75B
Stock-based compensation $1.35B$1.18B$1.16B$1.14B$1.14B$1.00B$977.0M$978.0M$962.0M$878.0M
Capital expenditure $4.83B$4.42B$4.54B$4.01B$3.65B$3.35B$3.50B$3.67B$3.28B$3.23B
Investing cash flow -$23.59B-$18.60B$878.0M-$12.37B-$8.68B-$20.82B-$6.19B-$3.17B-$14.87B-$4.76B
Financing cash flow -$5.54B-$3.13B-$15.82B-$8.87B-$14.05B-$6.12B-$18.02B-$18.51B-$7.67B-$8.55B
Buybacks $5.95B$2.43B$5.05B$6.04B$3.46B$3.22B$6.75B$5.87B$6.36B$8.98B

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000200406-26-000016.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 25B 50B 75B 100B Revenue, FY2016: 71.9B Gross profit, FY2016: 50.1B Net income, FY2016: 16.5B Revenue, FY2017: 76.5B Gross profit, FY2017: 51B Net income, FY2017: 1.3B Revenue, FY2018: 81.6B Gross profit, FY2018: 54.5B Net income, FY2018: 15.3B Revenue, FY2019: 82.1B Gross profit, FY2019: 54.5B Net income, FY2019: 15.1B Revenue, FY2020: 82.6B Gross profit, FY2020: 54.2B Net income, FY2020: 14.7B Revenue, FY2021: 78.7B Gross profit, FY2021: 55.3B Net income, FY2021: 20.9B Revenue, FY2022: 80B Gross profit, FY2022: 55.4B Net income, FY2022: 17.9B Revenue, FY2023: 85.2B Gross profit, FY2023: 58.6B Net income, FY2023: 35.2B Revenue, FY2024: 88.8B Gross profit, FY2024: 61.4B Net income, FY2024: 14.1B Revenue, FY2025: 94.2B Gross profit, FY2025: 63.9B Net income, FY2025: 26.8B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $71.89B $76.45B $81.58B $82.06B $82.58B $78.74B $79.99B $85.16B $88.82B $94.19B
Gross profit $50.10B $51.01B $54.49B $54.50B $54.16B $55.34B $55.39B $58.61B $61.35B $63.94B
Net income $16.54B $1.30B $15.30B $15.12B $14.71B $20.88B $17.94B $35.15B $14.07B $26.80B

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Regulation FD disclosure Item 7.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Other event Item 8.01
  • Officer or director change Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%
REGN REGENERON PHARMACEUTICALS, INC. $82.76B 19.4x 1.0%